Lixte Biotechnology Holdings, INC 8-K filings

Nomad Power Solutions, Inc. announced its common stock is now available for options trading on the Cboe Options Exchange under the symbol NMAD.

Nomad Power Solutions announces a significant upgrade to its Voyager mobile energy storage series, increasing capacity by up to 56% across its Eagle and Falcon models to 2.025 MWh without altering the physical footprint or deployment time.

Lixte Biotechnology Holdings, Inc. has completed its merger with Nomad Transportable Power Systems, Inc., rebranding to Nomad Power Solutions, Inc. and changing its ticker symbol to NMAD, signaling a strategic shift into the AI energy infrastructure market.

Lixte Biotechnology Holdings, Inc. has provided a $6.5 million loan to NOMAD Transportable Power Systems, Inc. ahead of their acquisition, expected to close around July 1, 2026.

Lixte Biotechnology Holdings, Inc. announced a definitive agreement to acquire Nomad Transportable Power Systems, Inc., a leader in mobile battery energy storage systems, and will be renamed NOMAD Power Solutions.

Lixte Biotechnology Holdings, Inc. has successfully closed a registered direct offering of common stock and pre-funded warrants, raising approximately $16.6 million in gross proceeds.

Lixte Biotechnology Holdings, Inc. announces a strategic transformation into an AI energy infrastructure equipment and services platform, seeking a buyer for its pharmaceutical operations.

Lixte Biotechnology Holdings, Inc. has cancelled existing stock options for key officers and directors, replacing them with an equivalent number of restricted share units.

Lixte Biotechnology Holdings, Inc. announced an amendment to its CEO Geordan Pursglove's employment agreement, increasing his annual base salary to $360,000, effective January 1, 2026.

Lixte Biotechnology Holdings, Inc. completed a share exchange with Orbit Capital Inc., converting Series C Preferred Stock into common stock and a stake in its Liora subsidiary.

Lixte Biotechnology Holdings, Inc. is doubling patient enrollment in its ovarian clear cell cancer clinical trial, expanding collaboration with GSK and MD Anderson Cancer Center.

Lixte Biotechnology Holdings, Inc. announced a $4.3 million registered direct offering of common stock and warrants, alongside the termination of a prior royalty agreement.

Lixte Biotechnology Holdings, Inc. stockholders approved the election of five directors, ratified its independent accounting firm, and increased the shares available under its 2020 Stock Incentive Plan at its Annual Meeting on December 8, 2025.

Lixte Biotechnology Holdings, Inc. has completed the acquisition of Liora Technologies Europe Ltd., marking its entry into the radiotherapy segment of cancer care.

LIXTE Biotechnology Holdings announced an initial $2.6 million purchase of Bitcoin and Ethereum to diversify its treasury and enable potential acquisitions.

LIXTE Biotechnology Holdings announced significant leadership changes, including new board members and a CFO, alongside a strategic relocation of its corporate headquarters to Boca Raton, Florida.

Lixte Biotechnology Holdings announced a corporate update, including two financings totaling $6.5 million, regaining Nasdaq compliance, and significant management and board changes.

Lixte Biotechnology Holdings, Inc. announced its Board of Directors approved allocating up to 25% of its corporate treasury to cryptocurrencies, including Bitcoin.

Lixte Biotechnology Holdings, Inc. announced the appointment of two new independent directors designated by Series B Preferred Stock holders and the resignation of its Chief Medical Officer.

LIXTE Biotechnology Holdings, Inc. announced it has regained compliance with Nasdaq's minimum equity requirement following recent capital raises totaling $6.5 million.

Lixte Biotechnology Holdings, Inc. announced that the medical journal Nature published findings validating the scientific premise of its ongoing clinical trials for Ovarian and Colorectal cancers, highlighting the potential of its compound LB100 to enhance immunotherapy.

Lixte Biotechnology Holdings, Inc. successfully closed a registered direct offering, raising approximately $1.5 million in gross proceeds through the sale of common stock and pre-funded warrants.

Lixte Biotechnology Holdings, Inc. has successfully closed a $5.0 million private placement, issuing common stock, pre-funded warrants, common stock warrants, and Series B Convertible Preferred Stock to accredited investors.

Lixte Biotechnology Holdings, Inc. has appointed Geordan Pursglove as its new Chief Executive Officer and Chairman of the Board, with the appointment and associated compensation critically dependent on the company securing financing to maintain its Nasdaq listing by July 3, 2025.

Lixte Biotechnology Holdings, Inc. reports the conversion of 350,000 shares of Series A Convertible Preferred Stock into 72,917 shares of common stock on May 16, 2025.

Lixte Biotechnology Holdings, Inc. receives an extension from Nasdaq to regain compliance with the minimum stockholders' equity requirement by July 3, 2025, to avoid delisting.

LIXTE Biotechnology Holdings, Inc. announces a new pre-clinical study in collaboration with the Netherlands Cancer Institute to investigate the potential of LB-100 in eliminating pre-cancerous cells in an aging population.

LIXTE Biotechnology announces progress in clinical trials for LB-100, targeting ovarian and colorectal cancer, along with a new patent license agreement with the NIH.

Lixte Biotechnology Holdings, Inc. amended its clinical trial agreement with Grupo Espaol de Investigacin en Sarcomas (GEIS), relieving the company of a $3.095 million financial obligation for the Phase 2 portion of a study.

Lixte Biotechnology Holdings, Inc. terminated its At-the-Market Sales Agreement with WallachBeth Capital LLC, effective March 18, 2025, and plans to explore alternative equity capital raising strategies.